Posted by ABMN Staff on Apr 23rd, 2024
Protara Therapeutics (NASDAQ:TARA – Free Report) had its price target lifted by Oppenheimer from $26.00 to $30.00 in a report published on Monday, Benzinga reports. Oppenheimer currently has an outperform rating on the stock.
Separately,...
More of this article »